NasdaqCM:CELCBiotechs
Why Celcuity (CELC) Is Up 5.1% After VIKTORIA-1 Success And Pipeline Expansion - And What's Next
Celcuity Inc. has reported that its Phase 3 VIKTORIA-1 trial of gedatolisib in HR-positive, HER2-negative advanced breast cancer met its primary progression-free survival endpoint, while first-quarter 2026 results showed a wider net loss of US$52.84 million and basic loss per share of US$0.97.
The company is reshaping its development plan by expanding the Phase 3 VIKTORIA-2 trial to cover both endocrine-resistant and endocrine-sensitive first-line patients and pursuing a patented...